EN DE
Watch XtalPi Holdings Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

XtalPi Holdings Limited (2228) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of XtalPi Holdings Limited stock HK$1.53, price HK$6.13, that is 75.0% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG7S12M1051

XH XtalPi Holdings Limited logo Thin data Nov 7, 2026

XtalPi Holdings Limited

2228 · HK
Very expensive, weak quality

Our calculation puts a fair price 75% below what the stock costs today.

Low debt
Upbeat coverage
Quality 42/100
Mixed Growth (revenue 3y +80.3 %/yr in CNY)
Loss over the last twelve months · -31.1% net margin (TTM) · fiscal year 2025 15.4%
Revenue last quarter 24% below a year ago.
Fair value HK$1.53 · Strongly overvalued
Negative free cash flow
Trails peers (1/10)
Narrow moat 15/100 · thin data
Thin data
Watch XtalPi Holdings Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$15.60 HK$3.26 Fair Value HK$1.53 Jun 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

29‑month range HK$3.26 – HK$15.60 · fair‑value band HK$1.14 – HK$1.67 · the HK$6.13 price screens above the HK$1.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow XtalPi Holdings in your weekly email

Every Wednesday you see whether XtalPi Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

XtalPi Holdings Limited operates as a research platform company in Mainland China, the United States, and internationally.

Show moreShow less

The company offers XmartChem, an intelligent synthesis workstation which automates the chemical synthesis process; ChemPlus, desktop solid dispensing device; PatSight, an optical chemical structure extraction tool for patents; and XFEP, a software for rapid FEP calculations using cloud computing.

It also provides XMolGen, a generative chemistry tool; and drug discovery solutions, such as hit discovery, hit or lead optimization, and biology capabilities, as well as PepiX, which generates stable peptides.

In addition, the company offers discovery chemistry solutions, including automation-aided chemical synthesis and focused library; and XtalGazer, a solid-state research solution.

It has a strategic collaboration with Pfizer to co-build an AI-driven molecular simulation research and development platform; DoveTree to develop therapeutics designed for multiple difficult-to-drug targets; and strategic partnership with an international biopharmaceutical company to develop oral small molecule therapeutics for a GPCR target.

The company was formerly known as QuantumPharm Inc. and changed its name to XtalPi Holdings Limited in December 2024. XtalPi Holdings Limited was founded in 2015 and is headquartered in Shenzhen, China.

Stock analysis

XtalPi Holdings Limited (2228) currently trades at HK$6.13, while our model-based Fair Value estimate is HK$1.53, 75% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of HK$1.81 per share, and 1 of the 10 models we run sit above the HK$6.13 price.

Bear case: the Multiples group reads lowest at HK$0.7200, and 9 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$1.14 (bear) to HK$1.67 (bull), the price of HK$6.13 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

XtalPi Holdings Limited reported revenue of 782M CNY in FY2025 versus 62.8M CNY in FY2021, a compound +87.8%/yr. Reported net income was 121M CNY in FY2025.

Key figures

Market cap HK$25.0B (≈ $3.2B) Mid · P/S ratio 38.3 · Net margin 15.4% · Return on equity −2.1% · Return on assets (EBIT) −11.5% (5-year average) · Operating margin −99.0% · Revenue (TTM) 679M CNY · Revenue growth (YoY) −23.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 56% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −75%, 2228 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (HK$0.2600 to HK$9.99). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear HK$1.14 Fair Value HK$1.53 Bull HK$1.67
Price HK$6.13 · Downside -75.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings HK$1.14 HK$1.66 HK$2.65 75
Residual Income HK$1.46 HK$1.53 HK$1.67 71
Growth-Adj P/E HK$1.01 HK$1.45 HK$1.88 67
All 10 models by family
DCF Models
Owner Earnings HK$1.14 HK$1.66 HK$2.65 75
Earnings-Based
Graham-Dodd HK$0.2200 HK$1.56 HK$2.19 63
Lynch FV HK$0.7500 HK$1.07 HK$1.40 61
PEG = 1.0 HK$0.7500 HK$1.07 HK$1.40 57
Multiples
P/E Multiple HK$0.5400 HK$0.7200 HK$0.9000 63
P/S Multiple HK$0.1900 HK$0.2600 HK$0.3200 58
P/B Multiple HK$7.49 HK$9.99 HK$12.49 55
Asset-Based
NCAV (Graham) HK$1.19 HK$1.81 HK$2.26 54
Economic Profit
Residual Income HK$1.46 HK$1.53 HK$1.67 71
Growth Earnings
Growth-Adj P/E HK$1.01 HK$1.45 HK$1.88 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 24
How much profit the company makes from its sales and capital
Quality Growth 92
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 96
Debt, balance sheet and risk of trouble
Investment 34
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 29
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+193.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+80.3%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−476.8% (2021) → −63.5% (2025)

2228 screens overvalued: fair value 75% below the price. Compare with Veeva Systems Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (38 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare XtalPi Holdings Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside −75.0% · Bottom 25%
Profitability
Return on assets 1.2% · Below median
Net margin (12 months) −31.1% · Bottom 25%
Operating margin (12 months) −99.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −23.9% · Bottom 25%
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 2.27× · Pricier than median
P/S (12 months) 31.36× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)0 · sector 46
PAST (return on equity)0 · sector 10
HEALTH (low debt)99 · sector 98
DIVIDEND (yield)0 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $303.73 $334.10 +10% vs 2228
HealthEquity, Inc HQY $103.63 $113.99 +10% vs 2228
Doximity, Inc DOCS $32.51 $35.76 +10% vs 2228
Inventurus Knowledge Solutions Limited IKS ₹1,657 ₹1,823 +10% vs 2228
Waystar Holding WAY $28.35 $29.10 +3% vs 2228
Winning Health Technology Group 300253 ¥7.03 ¥3.44 −51% vs 2228
Hinge Health, Inc HNGE $115.76 $51.25 −56% vs 2228
Pro Medicus Limited PME A$205.49 A$85.12 −59% vs 2228
BrightSpring Health Services, Inc BTSG $67.15 $25.72 −62% vs 2228
Privia Health Group PRVA $24.42 $5.52 −77% vs 2228

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

XtalPi Holdings Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "XtalPi Holdings Limited Fair Value". https://www.fairvalue-calculator.com/stock/2228

Frequently asked questions

Is XtalPi Holdings Limited (2228) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of HK$1.53 versus a price of HK$6.13, about 75% lower (overvalued).
What is the fair value of 2228?
Our model-based fair value for XtalPi Holdings Limited is HK$1.53 (as of Nov 7, 2026), built from audited fundamentals. The current price: HK$6.13.
What is the quality score of 2228?
XtalPi Holdings Limited has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for XtalPi Holdings Limited (2228)?
Our model-based price target is the fair value of HK$1.53 (as of Nov 7, 2026) from 10 valuation models. Cautious scenario HK$1.14, optimistic scenario HK$1.67. It is a calculation from audited fundamentals, not an analyst target.
What is the XtalPi Holdings Limited stock forecast for 2026?
Our models put fair value at HK$1.53, about 75% lower versus a price of HK$6.13 (overvalued). Cautious scenario HK$1.14, optimistic scenario HK$1.67. The calculation is refreshed regularly with new filings.
What is the revenue of XtalPi Holdings Limited (2228)?
XtalPi Holdings Limited reported trailing-twelve-month revenue of about 679M CNY (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of XtalPi Holdings Limited (2228)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For XtalPi Holdings Limited it is HK$1.53 per share (as of Nov 7, 2026), against a price of HK$6.13. It is the blended result of 10 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is XtalPi Holdings Limited stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 2228 trades above its calculated fair value: price HK$6.13, fair value HK$1.53, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2228?
No. The price is what the market pays today (HK$6.13); the fair value is what the company's own numbers justify (HK$1.53). For XtalPi Holdings Limited the two are HK$4.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is XtalPi Holdings Limited worth?
The market values XtalPi Holdings Limited at about HK$25.0B (market capitalisation, as of Nov 7, 2026). Per share that is HK$6.13; our models calculate a fair value of HK$1.53 per share.
What do the bullish and bearish scenarios say about 2228?
Our models span a range for XtalPi Holdings Limited: cautious scenario HK$1.14, base HK$1.53, optimistic HK$1.67 per share (as of Nov 7, 2026, price HK$6.13). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of XtalPi Holdings Limited (2228)?
Balance-sheet figures for XtalPi Holdings Limited (as of Nov 7, 2026): return on equity −2.1%, debt of 0.02 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 2228 from its 52-week high?
XtalPi Holdings Limited trades at HK$6.13, about 56% below its 52-week high of HK$13.97 and 5% above the low of HK$5.85 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.53 is for.
Which stocks are comparable to XtalPi Holdings Limited?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is XtalPi Holdings Limited stock attractive at the current price?
The data as of Nov 7, 2026: price HK$6.13, calculated fair value HK$1.53 (−75%), Quality Score 42/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2228 calculated?
We run XtalPi Holdings Limited through 10 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$1.53 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. XtalPi Holdings Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of XtalPi Holdings Limited (2228)?
The closing price on Nov 6, 2026 was HK$6.13. Our model-based fair value is HK$1.53, about 75% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with XtalPi Holdings Limited right now?
The price sits above even our optimistic bull case (HK$1.67). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of XtalPi Holdings Limited

How large is the market capitalisation of XtalPi Holdings Limited (2228)?
The market capitalisation of XtalPi Holdings Limited is HK$25.0B (≈ $3.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of XtalPi Holdings Limited (2228)?
The price-to-sales ratio of XtalPi Holdings Limited is 38.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of XtalPi Holdings Limited (2228)?
The net margin of XtalPi Holdings Limited is 15.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of XtalPi Holdings Limited (2228)?
The return on equity (ROE) of XtalPi Holdings Limited is −2.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of XtalPi Holdings Limited (2228)?
On an EBIT basis the return on assets of XtalPi Holdings Limited is −11.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of XtalPi Holdings Limited (2228)?
The operating margin of XtalPi Holdings Limited is −99.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at XtalPi Holdings Limited (2228)?
Revenue at XtalPi Holdings Limited is growing −23.9% versus a year earlier (3y avg +80.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does XtalPi Holdings Limited (2228) generate?
The free cash flow of XtalPi Holdings Limited is −200M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does XtalPi Holdings Limited (2228) hold?
XtalPi Holdings Limited holds more cash than debt, 2.1B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch XtalPi Holdings Limited in the live analysis

One click puts XtalPi Holdings Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.